Vinorelbine: A new antineoplastic drug for the treatment of non-small-cell lung cancer

Annals of Pharmacotherapy

Volumn 30, Issue 5, 1996, Pages 501-505

  Jones, Suzanne Fields ^a   Burris III, Howard A ^b  

^a Tyler Hematology Oncology   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NAVELBINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; THORAX PAIN;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; VINBLASTINE;

EID: 0029970414     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000513     Document Type: Article

References (29)

1. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, et al. Polychemotherapy in advanced non small cell lung cancer: a metaanalysis. Lancet 1993;342:19-21.
2. Potier P. The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 1989;16(suppl 4):2-4.
3. Binet S, Chineau E, Fellous A, Lataste H, Krikorian A, Couzinier JP, et al. Immunofluorescence study of the action of Navelbine, vincristine, and vinblastine on mitotic and axonal microtubules. Int J Cancer 1990;46:2626.
4. Wargin WA, Lucas VS. The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol 1994;21(suppl 10):21-7.
5. Cros S, Wright M, Morimoto M, Lataste H, Couzinier JP, Krikorian A. Experimental antitumor activity of Navelbine. Semin Oncol 1989;16 (suppl 4):15-20.
6. Mathe G, Reizenstein P. Phase I pharmacologic study of a new vinca alkaloid: Navelbine. Cancer Lett 1985;27:285-93
7. Favre R, Garnier G, Depierre A, Samak R, Cano JP, Carcassonne Y. A phase I study of navelbine (nov-5′-anhydrovinblastine). Recent Adv Chemother 1985:641-2.
8. Furuse K, Niitani H. Wakui A, Hasegawa K, Furue H, Saito T, et al. Phase I study on vinorelbine (Navelbine) by single or intermittent administration (abstract). Invest New Drugs 1989;7:456.
9. Berthaud P, LeChevalier T, Ruffie P, Baldeyrou P, Arriagada R, Besson F, et al. Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1992;28A:1863-5
10. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991;14:115-9.
11. Yokoyama A, Furuse K, Niitani H. Multi-institutional phase II study of Navelbine (vinorelbine) in non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 1992;11:287.
12. Lonardi F, Pavanato G, Jirillo A, Ferrari V, Bonciarelli G, Balli M. Vinorelbine (VNB) as single-agent chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (pts) (abstract). Proc Am Soc Clin Oncol 1994;13:338.
13. Crivellari D, Veronesi A, Sacco C, Magri MD, Buonadonna A, Foladore S, et al. Phase II study of vinorelbine (V) in 50 patients (pts) with non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1994;13:355.
14. Depierre A, Chastang CL, Quoix E, Lebeau B, Blanchon F, Paillot N, et al. Vinorelbine versus vinorelbine plus, cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994;5:37-42.
15. LeChevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelhine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
16. O'Rourke M, Crawford J, Schiller J, Laufman L, Yanovich S, Ozer H, et al. Survival advantage for patients with stage IV NSCLC treated with single agent Navelbine in a randomized controlled trial (abstract). Proc Am Soc Clin Oncol 1993;12:343.
17. Moinpour CM. Measuring quality of life: an emerging science. Semin Oncol 1994;21(suppl 10);48-63.
18. Kusunoki Y, Furuse K, Yamori S, Niitani H, Sakuma A, Fukuoka M, et al. Randomized phase II study of vinorelbine (VNR) vs vindesine (VDS) in previously untreated non-small cell lung cancer (NSCLC) (abstract). Lung Cancer: J Int Assoc Study Lung Cancer 1994;11(suppl 1):113.
19. Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994;2(supp 110):42-7.
20. Package insert, Navelbine (vinorelbine) Research Triangle Park, NC: Burroughs Wellcome, December 1994.
21. Rittenberg CN, Gralla RJ, Rehmeyer TA. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine). Oncol Nurs Forum 1995;22:707-10.
22. Bergeron A, Raffy O, Vannetzel JM. Myocardial ischemia and infarction associated with vinorelbine. J Clin Oncol 1995;13:531-2.
23. Feld R, Ginsberg RJ, Payne DG, Shephard FA. Lung. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical oncology. New York: Churchill Livingstone, 1995:1083-153.
24. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-41.
25. Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 1990;8:1301-9.
26. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced nonsmall-cell lung cancer. J Natl Cancer Inst 1993;85:384-8
27. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993;85:388-94.
28. Kreisman H, Ginsberg S, Propert KJ, Richards F, Graziano S, Green M. Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Cancer Treat Rep 1987;71:1049-52.
29. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Bhim RH, Green MD, Mason B, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602-13.